Robert Simon MD

Alteron Therapeutics LLC, based in Kalamazoo, MI, is dedicated to addressing unmet medical needs in the treatment of neurodegenerative diseases such as ALS, Alzheimer's disease, and cystic fibrosis. The company focuses on developing groundbreaking therapies that target TDP43 toxicity, a significant contributor to neuronal damage, with the aim of providing hope and relief to patients worldwide. Through its innovative ALTAdrug series, Alteron Therapeutics aims to disrupt the detrimental interactions of TDP43 by specifically targeting its guanine pocket, potentially halting or reversing neurodegenerative processes. Their leading drug candidate is designed for optimal patient convenience and efficacy, demonstrating the ability to cross the blood-brain barrier and rapidly reverse ALS symptoms while maintaining an excellent safety profile. Generated from the website